Halozyme Therapeutics, Inc. (0J2O.L)
USD 61.37
(0.79%)
USD 61.37
(0.79%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 281.59 Million USD | 39.31% |
| 2022 | 202.12 Million USD | -49.81% |
| 2021 | 402.71 Million USD | 211.97% |
| 2020 | 129.08 Million USD | 278.69% |
| 2019 | -72.24 Million USD | 10.07% |
| 2018 | -80.33 Million USD | -227.57% |
| 2017 | 62.97 Million USD | 161.12% |
| 2016 | -103.02 Million USD | -219.64% |
| 2015 | -32.23 Million USD | 52.86% |
| 2014 | -68.37 Million USD | 18.09% |
| 2013 | -83.47 Million USD | -55.88% |
| 2012 | -53.55 Million USD | -170.88% |
| 2011 | -19.76 Million USD | 62.87% |
| 2010 | -53.24 Million USD | 8.77% |
| 2009 | -58.36 Million USD | -19.95% |
| 2008 | -48.65 Million USD | -103.61% |
| 2007 | -23.89 Million USD | -61.99% |
| 2006 | -14.75 Million USD | -11.12% |
| 2005 | -13.27 Million USD | -46.02% |
| 2004 | -9.09 Million USD | -11394.83% |
| 2003 | -79.09 Thousand USD | -21.19% |
| 2002 | -65.26 Thousand USD | -64.59% |
| 2001 | -39.65 Thousand USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 93.24 Million USD | 21.38% |
| 2024 Q1 | 76.82 Million USD | -10.03% |
| 2024 Q3 | 137.01 Million USD | 46.94% |
| 2023 FY | 281.59 Million USD | 39.31% |
| 2023 Q1 | 39.61 Million USD | -31.35% |
| 2023 Q2 | 74.75 Million USD | 88.7% |
| 2023 Q4 | 85.38 Million USD | 4.34% |
| 2023 Q3 | 81.83 Million USD | 9.48% |
| 2022 Q4 | 57.7 Million USD | -6.38% |
| 2022 Q3 | 61.63 Million USD | 171.69% |
| 2022 Q1 | 60.1 Million USD | -9.98% |
| 2022 Q2 | 22.68 Million USD | -62.26% |
| 2022 FY | 202.12 Million USD | -49.81% |
| 2021 Q4 | 66.77 Million USD | -69.17% |
| 2021 Q3 | 216.58 Million USD | 136.82% |
| 2021 Q1 | 27.89 Million USD | -61.87% |
| 2021 Q2 | 91.45 Million USD | 227.87% |
| 2021 FY | 402.71 Million USD | 211.97% |
| 2020 Q3 | 36.2 Million USD | 40.24% |
| 2020 FY | 129.08 Million USD | 278.69% |
| 2020 Q4 | 73.16 Million USD | 102.07% |
| 2020 Q2 | 25.81 Million USD | 523.02% |
| 2020 Q1 | -6.1 Million USD | 82.26% |
| 2019 Q1 | 1.79 Million USD | 184.48% |
| 2019 FY | -72.24 Million USD | 10.07% |
| 2019 Q4 | -34.39 Million USD | -37.51% |
| 2019 Q3 | -25.01 Million USD | -71.05% |
| 2019 Q2 | -14.62 Million USD | -914.25% |
| 2018 Q4 | -2.12 Million USD | 92.37% |
| 2018 FY | -80.33 Million USD | -227.57% |
| 2018 Q1 | -27.46 Million USD | -122.17% |
| 2018 Q2 | -22.89 Million USD | 16.63% |
| 2018 Q3 | -27.85 Million USD | -21.65% |
| 2017 Q3 | 2.74 Million USD | 108.94% |
| 2017 Q4 | 123.88 Million USD | 4406.44% |
| 2017 Q1 | -32.89 Million USD | -20.12% |
| 2017 Q2 | -30.76 Million USD | 6.49% |
| 2017 FY | 62.97 Million USD | 161.12% |
| 2016 Q3 | -28.94 Million USD | -7.71% |
| 2016 Q2 | -26.87 Million USD | -35.62% |
| 2016 Q1 | -19.81 Million USD | -558.92% |
| 2016 FY | -103.02 Million USD | -219.64% |
| 2016 Q4 | -27.38 Million USD | 5.39% |
| 2015 Q3 | -24.46 Million USD | -910.2% |
| 2015 Q1 | -15.1 Million USD | -186.46% |
| 2015 Q4 | 4.31 Million USD | 117.65% |
| 2015 FY | -32.23 Million USD | 52.86% |
| 2015 Q2 | 3.01 Million USD | 119.98% |
| 2014 Q3 | -20.28 Million USD | -24.62% |
| 2014 FY | -68.37 Million USD | 18.09% |
| 2014 Q4 | -5.27 Million USD | 73.99% |
| 2014 Q2 | -16.27 Million USD | 38.7% |
| 2014 Q1 | -26.54 Million USD | -20.75% |
| 2013 Q4 | -21.98 Million USD | -13.96% |
| 2013 Q1 | -19.28 Million USD | -337.79% |
| 2013 FY | -83.47 Million USD | -55.88% |
| 2013 Q2 | -22.91 Million USD | -18.78% |
| 2013 Q3 | -19.29 Million USD | 15.8% |
| 2012 Q3 | -20 Million USD | -42.68% |
| 2012 Q1 | -15.11 Million USD | 17.9% |
| 2012 Q2 | -14.02 Million USD | 7.26% |
| 2012 Q4 | -4.4 Million USD | 77.98% |
| 2012 FY | -53.55 Million USD | -170.88% |
| 2011 Q1 | -9.63 Million USD | 42.96% |
| 2011 FY | -19.76 Million USD | 62.87% |
| 2011 Q4 | -18.41 Million USD | -456.53% |
| 2011 Q3 | 5.16 Million USD | 65.75% |
| 2011 Q2 | 3.11 Million USD | 132.34% |
| 2010 Q3 | -12.4 Million USD | -2.13% |
| 2010 Q4 | -16.89 Million USD | -36.13% |
| 2010 FY | -53.24 Million USD | 8.77% |
| 2010 Q1 | -11.78 Million USD | 6.93% |
| 2010 Q2 | -12.15 Million USD | -3.08% |
| 2009 Q4 | -12.66 Million USD | 8.95% |
| 2009 Q2 | -17.06 Million USD | -15.85% |
| 2009 Q3 | -13.91 Million USD | 18.46% |
| 2009 FY | -58.36 Million USD | -19.95% |
| 2009 Q1 | -14.72 Million USD | 12.48% |
| 2008 Q4 | -16.82 Million USD | -54.76% |
| 2008 Q2 | -11 Million USD | -10.53% |
| 2008 Q1 | -9.95 Million USD | -14.3% |
| 2008 FY | -48.65 Million USD | -103.61% |
| 2008 Q3 | -10.87 Million USD | 1.18% |
| 2007 Q4 | -8.7 Million USD | -23.9% |
| 2007 Q3 | -7.02 Million USD | -46.38% |
| 2007 Q2 | -4.8 Million USD | -43.02% |
| 2007 Q1 | -3.35 Million USD | 23.31% |
| 2007 FY | -23.89 Million USD | -61.99% |
| 2006 Q2 | -3.23 Million USD | 7.38% |
| 2006 Q1 | -3.49 Million USD | 0.66% |
| 2006 FY | -14.75 Million USD | -11.12% |
| 2006 Q4 | -4.37 Million USD | -19.91% |
| 2006 Q3 | -3.65 Million USD | -12.94% |
| 2005 Q3 | -3.7 Million USD | -29.01% |
| 2005 Q4 | -3.51 Million USD | 5.05% |
| 2005 Q1 | -3.19 Million USD | -28.8% |
| 2005 Q2 | -2.86 Million USD | 10.17% |
| 2005 FY | -13.27 Million USD | -46.02% |
| 2004 Q2 | -2.07 Million USD | -61.53% |
| 2004 Q3 | -3.25 Million USD | -56.8% |
| 2004 Q1 | -1.28 Million USD | -2282.18% |
| 2004 FY | -9.09 Million USD | -11394.83% |
| 2004 Q4 | -2.47 Million USD | 23.79% |
| 2003 Q4 | -53.91 Thousand USD | -469.84% |
| 2003 Q3 | -9462.00 USD | -95.13% |
| 2003 FY | -79.09 Thousand USD | -21.19% |
| 2003 Q1 | -9874.00 USD | 78.51% |
| 2003 Q2 | -4849.00 USD | 50.89% |
| 2002 FY | -65.26 Thousand USD | -64.59% |
| 2002 Q4 | -45.94 Thousand USD | -264.32% |
| 2002 Q1 | 9362.00 USD | 0.0% |
| 2002 Q2 | -16.07 Thousand USD | -271.69% |
| 2002 Q3 | -12.61 Thousand USD | 21.55% |
| 2001 FY | -39.65 Thousand USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Editas Medicine, Inc. | -153.21 Million USD | 283.785% |
| Dynavax Technologies Corporation | -6.38 Million USD | 4507.482% |
| Cara Therapeutics, Inc. | -118.51 Million USD | 337.606% |
| Walgreens Boots Alliance, Inc. | -8.63 Billion USD | 103.261% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | -21297.72% |
| Perrigo Company plc | -12.7 Million USD | 2317.276% |
| Atara Biotherapeutics, Inc. | -276.12 Million USD | 201.98% |
| Illumina, Inc. | -1.16 Billion USD | 124.254% |
| Thermo Fisher Scientific Inc. | 5.99 Billion USD | 95.303% |
| Nektar Therapeutics | -276.05 Million USD | 202.006% |
| Iovance Biotherapeutics, Inc. | -444.03 Million USD | 163.417% |
| IQVIA Holdings Inc. | 1.35 Billion USD | 79.264% |
| Heron Therapeutics, Inc. | -110.55 Million USD | 354.7% |
| Unity Biotechnology, Inc. | -39.86 Million USD | 806.458% |
| BioMarin Pharmaceutical Inc. | 167.64 Million USD | -67.97% |
| Waters Corporation | 642.23 Million USD | 56.154% |
| Biogen Inc. | 1.16 Billion USD | 75.748% |
| Sangamo Therapeutics, Inc. | -257.83 Million USD | 209.217% |
| Adicet Bio, Inc. | -142.65 Million USD | 297.391% |
| Evolus, Inc. | -61.68 Million USD | 556.503% |
| bluebird bio, Inc. | -211.91 Million USD | 232.882% |
| Aclaris Therapeutics, Inc. | -88.48 Million USD | 418.254% |
| Esperion Therapeutics, Inc. | -209.24 Million USD | 234.574% |
| FibroGen, Inc. | -284.23 Million USD | 199.072% |
| Agilent Technologies, Inc. | 1.24 Billion USD | 77.291% |
| Homology Medicines, Inc. | -53.74 Million USD | 623.964% |
| Geron Corporation | -184.12 Million USD | 252.935% |
| Alnylam Pharmaceuticals, Inc. | -440.24 Million USD | 163.963% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.6 Million USD | 731.33% |
| Amicus Therapeutics, Inc. | -151.58 Million USD | 285.768% |
| Myriad Genetics, Inc. | -112 Million USD | 351.423% |
| Regeneron Pharmaceuticals, Inc. | 3.95 Billion USD | 92.878% |
| OPKO Health, Inc. | -188.86 Million USD | 249.1% |
| Viking Therapeutics, Inc. | -85.89 Million USD | 427.835% |
| Intellia Therapeutics, Inc. | -481.19 Million USD | 158.52% |
| Zoetis Inc. | 2.34 Billion USD | 87.987% |
| Abeona Therapeutics Inc. | -54.18 Million USD | 619.661% |
| Mettler-Toledo International Inc. | 788.77 Million USD | 64.3% |
| Exelixis, Inc. | 207.76 Million USD | -35.535% |
| Vertex Pharmaceuticals Incorporated | 3.61 Billion USD | 92.22% |
| uniQure N.V. | -308.47 Million USD | 191.285% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | 767.3% |
| Anavex Life Sciences Corp. | -47.5 Million USD | 692.767% |
| Axsome Therapeutics, Inc. | -239.23 Million USD | 217.705% |
| Verastem, Inc. | -87.36 Million USD | 422.312% |
| Imunon, Inc. | -19.51 Million USD | 1542.964% |
| Ionis Pharmaceuticals, Inc. | -366.28 Million USD | 176.878% |
| Sarepta Therapeutics, Inc. | -535.97 Million USD | 152.538% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | -12.773% |
| Corcept Therapeutics Incorporated | 106.14 Million USD | -165.304% |
| TG Therapeutics, Inc. | 12.67 Million USD | -2122.175% |
| Blueprint Medicines Corporation | -506.98 Million USD | 155.543% |
| Insmed Incorporated | -749.56 Million USD | 137.568% |
| Agios Pharmaceuticals, Inc. | -352.08 Million USD | 179.978% |
| Incyte Corporation | 597.59 Million USD | 52.879% |
| Emergent BioSolutions Inc. | -760.5 Million USD | 137.027% |